Form 4: NVNO Director Sells Shares Under 10b5-1 Plan
Insider Transaction Report
enVVeno Medical Corp Director Francis Duhay sold 4,900 shares of common stock for $0.3556 per share on December 11, 2025, as part of a pre-arranged 10b5-1 trading plan.
Summary
- Francis Duhay, a Director of enVVeno Medical Corp (NVNO), reported the sale of 4,900 shares of common stock.
- The transaction occurred on December 11, 2025.
- The shares were sold at a weighted-average price of $0.3556 per share, with individual trades ranging from $0.3554 to $0.3573.
- This sale was executed pursuant to a Rule 10b5-1 trading plan adopted by Mr. Duhay in June 2025.
- Following this transaction, Mr. Duhay beneficially owns 92,544 shares of enVVeno Medical Corp common stock.
Sentiment
Score: 4
Explanation: The sentiment is slightly negative due to a director selling shares, even though it was part of a pre-arranged 10b5-1 plan. While 10b5-1 plans mitigate concerns about opportunistic trading, any reduction in insider ownership can be viewed with caution by investors.
Positives
- The transaction was conducted under a Rule 10b5-1 trading plan, indicating it was pre-scheduled and not based on immediate, non-public information, which enhances transparency.
Negatives
- A director selling shares, even under a 10b5-1 plan, can sometimes be perceived negatively by the market as it reduces insider ownership.
Risks
- Potential negative market perception or investor sentiment due to insider selling.
- The sale price of $0.3556 per share is relatively low, which could reflect current market valuation or future expectations, though this is speculative without more context.
Future Outlook
N/A. This filing reports a past insider transaction and does not provide forward-looking statements or guidance.
Industry Context
N/A. This filing is a routine insider transaction report and does not provide information relevant to broader industry trends or competitive analysis.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Insider Trading Plan Disclosure | The transaction was executed pursuant to a Rule 10b5-1 trading plan adopted in June 2025, which allows insiders to pre-arrange trades to avoid accusations of trading on material non-public information. | June 2025 (plan adoption), 12/11/2025 (transaction) | Enhances transparency and provides an affirmative defense against insider trading allegations, aligning with good corporate governance practices for insider transactions. |
Stakeholder Impact
- Shareholders: May view the director's sale with slight caution, although the 10b5-1 plan provides context. It reduces the director's direct equity stake in the company.
Key Dates
| Date | Description |
|---|---|
| June 2025 | Rule 10b5-1 trading plan adopted by Francis Duhay. |
| 12/11/2025 | Date of common stock transaction by Francis Duhay. |
| 12/12/2025 | Date the Form 4 was signed and filed. |
Keywords
enVVeno Medical Corp, NVNO, Form 4, Insider Trading, Director Stock Sale, 10b5-1 Plan, Equity Transaction, Francis Duhay
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.